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The susceptibility of CD46 (human membrane cofactor protein) transgenic mice to measles virus (MV) infection was
investigated. Cell cultures (lung and kidney) established from transgenic and control mice showed that although both could
be infected only those from the CD461 mice gave fusion. A complete round of replication with the release of infectious virus
was detected exclusively in the transgenic cell cultures whose permissiveness to MV was markedly less than that of Vero
cells. The ability of MV to replicate in vivo in mice was studied using both vaccine and laboratory-adapted wild-type strains
of virus. After intraperitoneal and intranasal inoculations of transgenic mice, virus replication could not be detected. In
contrast intracerebral inoculation induced infection in both transgenic and nontransgenic mice. Our results from in vitro
infection studies support the hypothesis that CD46 is a major host cell factor involved in the MV-induced fusion process and
MV entry. The studies further indicate that MV tropism is not governed solely by the expression of the CD46 gene and that
the high efficiency of the replicative cycles characteristic of fully permissive host cells requires additional factors, which are
lacking in both transgenic and nontransgenic mice. © 1998 Academic Press
INTRODUCTION
Measles is one of the primary health problems for
infants in the developing world. The widespread use of
live attenuated vaccines has reduced the prevalence
of disease in industrialized countries (Bloom, 1989).
The natural host range of measles virus (MV) is re-
stricted to man in whom the typical clinical infection is
characterized by viral replication in cells of the lym-
phoid system with subsequent dissemination to tis-
sues throughout the body (Esolen et al., 1993; Karp et
al., 1996).
The hemagglutinin (H) and fusion (F) envelope gly-
coproteins are involved in the receptor-mediated bind-
ing and entry of MV into cells. A host cell receptor for
MV was identified as the human membrane cofactor
protein, CD46 (Do¨rig et al., 1993; Naniche et al., 1993),
a member of the regulator of the complement activa-
tion (RCA) family. Antibodies to CD46 inhibit MV infec-
tion in permissive host cells (Naniche et al., 1993), and
transfection of a cDNA coding for CD46 into murine or
hamster cells nonpermissive for MV permits MV rep-
lication confirming the role of CD46 as a receptor for
MV (Naniche et al., 1993; Manchester et al., 1994,
1995; Yanagi et al., 1994). Studies in vitro and in vivo
reported a restriction of MV replication in cells in both
CD46 transgenic and nontransgenic murine cells (Hor-
vat et al., 1996).
In vivo animal models are essential to study the effects
of the individual viral components in the context of the
immune system and to evaluate the efficacy of novel
vaccine and therapeutic strategies. Rodents can be in-
fected with neuroadapted strains, but these infections
are restricted to the central nervous system (Liebert and
Finke, 1995). The SCID mouse with co-implants of human
fetal thymus and liver cells has recently proven valuable
for the study of certain aspects of MV infection (Au-
waerter et al., 1996), but this artificial system presents
problems in studying a broader range of virus-host inter-
actions involved in systemic MV infections.
In search of a suitable small animal model suscep-
tible to MV, transgenic mice expressing a genomic
copy of CD46 were studied for their permissivity to MV
infection both in vivo and in vitro. Thus such mice can
potentially express the different isoforms of CD46. We
show that although cell cultures established from the
CD461 mice can be infected by MV, we were only able
to detect virus infection in vivo after intracerebral in-
oculation of mice.
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RESULTS
In vitro infection studies
To test the susceptibility to MV infection, cultures of
lung and kidney from transgenic mice and nontransgenic
controls were prepared. The transgenic mouse cells
were examined with a panel of anti-CD46 MAbs, and
their FACS profiles were similar to those found in cells of
human origin (Table 1, Fig. 1). To test the fusability of the
CD46-expressing cells, they were infected with a vac-
cinia recombinant expression the MV F and H proteins.
This resulted in syncytia formation in the CD461 but not
in CD462 cells (Fig. 2).
Cultures from lungs and kidneys were infected with
the Halle´ strain of MV (m.o.i. 0.5 or 3 PFU/cell). Forty-
eight hours after infection, syncytia appeared in cultures
of transgenic mouse and Vero cell cultures (positive
controls), whereas syncytia were not observed in cul-
tures established from nontransgenic mouse cells (Fig.
2). Similarly syncytia developed after infection with Ed-
monston, Y15, and MA93F virus strains in transgenic
mouse cell cultures and not in corresponding nontrans-
genic mouse cell cultures.
In contrast to MV infection in Vero cell cultures, the
syncytia in the transgenic mouse cells did not spread to
involve the entire monolayer. By indirect IF using anti-N,
-M, -F, and -H MAbs intracellular viral antigen was de-
tected in both transgenic and nontransgenic cell cul-
tures. The majority of CD461 cells expressed viral anti-
gen 44 h postinfection, whereas only a few IF positive
cells in nontransgenic cells were observed at this time
(Fig. 3).
To test for infectious viral progeny after primary pas-
sage in mouse cells, cell culture supernatants or cell
lysates (freeze-thawed cells) were passaged onto either
mouse cell cultures or Vero cell cultures. Viral passage
in mouse cell cultures were achieved from cell lysates of
transgenic cultures but with a decreasing efficiency on
further passage (Fig. 4). Cell culture supernatants of
transgenic cells, but not of nontransgenic cells, con-
tained low levels of infectious virus. When assayed in
Vero cells, titers of up to 102 TCID50/ml were detected in
supernatants of transgenic cells but not in nontransgenic
cells (data not shown).
Further attempts to isolate MV in transgenic mouse
cells by five consecutive blind passages performed with
the Halle´, Edmonston, and MA93F strains with 6- to
7-day intervals using trypsinized cells, culture superna-
tants, or cell lysates failed (data not shown).
In vivo infection studies
To study the susceptibility of transgenic mice to MV
infection, mice were inoculated intraperitoneally, intrana-
sally, or intracerebrally.
Intraperitoneal and intranasal infection experiments.
Transgenic mice and their negative control litter mates
(BALB/c 3 Black6/SJL) were inoculated intraperitoneally
with the Halle´ strain of MV (Table 2, Experiment 1). PBMC
and cryo sections of lung, thymus, or spleen were exam-
ined for viral antigen by IF. MV antigen could not be
detected in either the transgenic or control mice 3–9
days postinoculation (Table 2, Experiment 2). Similarly
infectious virus was not detected and no serum neutral-
izing antibodies were found in the mice 3 weeks after
inoculation (Table 2, Experiment 2).
Further studies were performed using a different MV
strain (Ma93F), but neither viral antigen nor infectious
virus could be detected (Table 2, Experiment 3). Only on
Day 4 postinoculation were viral transcripts detected in
two transgenic mice (Table 3).
In a further series of experiments, the amount of virus
was increased (2.4 3 107 PFU/mouse, Experiment 4).
Intranasal infection was performed in 16 transgenic mice
of which 12 were also inoculated intraperitoneally. Mice
were sacrificed on Days 2, 5, 7, 14, and 21 postinocula-
tion and examined for the presence of viral transcripts.
On Days 2, 5, and 7 postinoculation, MV-F transcripts
TABLE 1
FACS Analysis of Expression of CD46 on Transgenic and Non-Transgenic Cell Lines of Murine Origin
and on Cell Lines of Simian and Human Origin
Cell Type
MAb anti-CD46, SCR 1 MAb anti-CD46, SCR 4
MCI20.6 29 E8/5 E12/4 13/42 10/88
Mouse transgenica 1 1 1 1 1 1
Mouse non-transgenica 2 2 2 2 2 2
Vero 2 1 2 2 1 1
Hela 1 1 1 1 1 1
Note. Data on monoclonal antibody reactivities; 1, positive; 2, negative; SCR, short consensus region.
a Results from kidney and lung cell cultures established from two different mice.
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were detected in tissue samples (lung, kidney, intestine)
of five transgenic mice (Table 3). Virus isolation was
attempted from lung tissue of two mice 5 days after
intranasal inoculation with negative results, and no viral
antibodies were detected in serum samples 4 or 20
weeks after inoculation (Table 2).
Intracerebral challenge experiments. Intracerebral in-
fection with the Yamagata and the Edmonston strains
was performed in 4- to 5-week-old mice (Table 2, Exper-
iments 5 and 6). Infectious virus was not recovered from
the brains of the mice assayed on Days 7 and 14 posti-
noculation (Table 2). Cryo sections of brain tissue on Day
14 postinoculation were examined for viral antigen by IF
employing the anti-N MAb 25 (Giraudon et al., 1988). MV
antigen was detected in the hippocampus of transgenic
and nontransgenic mice inoculated with the Yamagata
and Edmonston strains, respectively (Table 2, Experi-
ments 5 and 6). The presence of viral RNA was examined
in different structures of the brain 4–28 days after infec-
tion. Both in Edmonston- and Yamagata-inoculated mice,
FIG. 1. Cells (5 3 105 cells) of established kidney (Kidney CD46) and lung (Lung CD46) cell cultures from CD46 transgenic mice, of HeLa cells, and
of lymphocytes for man (man) and transgenic mouse (mouse) were preincubated with PBS (Control FITC) or MAb 20.6, alternatively MAb E8/5,
washed, exposed to a FITC-labeled secondary antibody, and analyzed by cytofluorometry. Fluorescence histograms are shown in which fluorescence
intensity (x axis) is plotted versus relative cell number (y axis).
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FIG. 2. Lung cell cultures of a CD46 transgenic mouse (1, 2, 5, and 6) and a normal mouse (3, 4, 7, and 8); 24 h after infection with vaccinia virus
recombinant encoding the MV H and F proteins (1 and 3) and mock-infection (2 and 4); 3 days after MV infection (Halle´ strain) (5 and 7) and
mock-infection (6 and 8).
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MV-F transcripts were detected from Day 4 through Day
28 (Table 4, Fig. 5). It should be noted that it can not be
totally excluded that a small amount of amplicons at
early time points postinoculation could derive from viral
mRNA of the inoculum. Our results, however, clearly
indicated that the hybridization signals of amplicons de-
riving from a constant amount of total RNA increased
within the first week postinoculation (data not shown).
This time-related kinetics of detectable amplicons pro-
vided further evidence that an active transcription/repli-
cation of viral nucleic acids has taken place in the mouse
brains.
There was no pronounced difference in the presence,
the spread, and the persistence of detectable viral nu-
cleic acids in the transgenic and nontransgenic mice.
There was, however, a specific distribution of virus within
the different structures of the brain. Thus in the cerebel-
lum, MV appeared to have a restricted growth as com-
pared to the frontal cortex and the hippocampus (Table
4). In 19 of 20 transgenic mice, viral RNA was detected in
the hippocampus, in 15 of the 20 mice viral RNA was
detected in the cortex, whereas only 7 of the 20 mice had
detectable viral transcripts in the cerebellum. On Day 28
after inoculation of the Yamagata strain, viral transcripts
were no longer detectable in the cerebellum in either
transgenic or in nontransgenic mice (Table 4).
Overt clinical symptoms or death were observed in 3
of the 50 intracerebrally MV-inoculated mice, all of which
were nontransgenic. Between Days 14 and 21, two mice
inoculated with the Yamagata strain showed clinical
signs of disease with retarded growth, ruffled fur, and
cramps; one died the day after the clinical symptoms
were observed (Day 16 postinoculation), the other was
sacrificed on Day 21 (data not shown). Cerebral edema
was observed (postmortem) on Days 4, 7 and 28 posti-
noculation in three mice (two transgenic and one non-
transgenic) exclusively after inoculation with the Yama-
gata strain. No signs of disease or cerebral edema were
observed in the sham-inoculated mice.
DISCUSSION
Our impetus of the present study is the need for a
small animal model for MV infection. In the CD46 trans-
FIG 3. Lung cell cultures of a CD46 transgenic mouse (1) and a normal mouse (2) 44 h after MV inoculation (Edmonston strain). The cells were
assayed in indirect immunofluorescence with a MAb against the MV N protein.
FIG. 4. Replication of MV in CD46-transgenic and nontransgenic
mouse cell cultures. The Halle´ and Edmonston strains (106 TCID50)
propagated and titrated in Vero cells were passaged in lung cell
cultures of CD46-transgenic (E) and nontransgenic mice (3). Both
curves represent results obtained with the Halle´ and the Edmonston
strains. Cell monolayers were incubated with MV (starting with a m.o.i.
of 3) overnight at 37°C, then the infecting virus was washed off and
replaced with fresh medium, and the cells were further incubated for 4
days. Lysates of these incubations were prepared by freeze-thawing
and inoculated onto new mouse cell monolayers. Virus passaged in
mouse cell cultures was titrated by determining the highest dilutions
that infected 50% of the mouse cell cultures (TCID50) as determined by
IF detection of intracellular MV antigen.
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genic mouse lines investigated, the CD46 gene was
expressed in a number of tissues and in B and T lym-
phocytes at levels similar to man. An advantage to using
a genomic construct to generate transgenic mice is that
the tissue expression of the various CD46 isoforms ap-
pears to have the same pattern as that of corresponding
human tissues (Johnstone et al., 1993). It has been dem-
onstrated that four major isoforms of glycosylated CD46
in transfected rodent cells bind MV hemagglutinin with
their first and second short consensus regions (SCR)
(Iwata et al., 1995; Manchester et al., 1995).
The in vitro cultured transgenic lung and kidney cells
permitted MV attachment and syncytia formation. Simi-
larly, the CD46 transgene was found to render the cells
capable of syncytia formation upon infection with a vac-
cinia recombinant expressing the H and F proteins,
whereas parallel nontransgenic mouse cells did not pro-
duce syncytia. Low amount of MV were detected in cell
culture supernatants only in the transgenic mouse cells
and not in corresponding nontransgenic mouse cells.
After intraperitoneal and intranasal infection, viral tran-
scripts were detected only in tissues of transgenic mice.
They were limited to the lung, intestines, and kidneys, being
detectable only during the first week postinoculation. No
infectious virus could be isolated from any of the animals.
Reports from in vivo studies in transgenic rats also
reported the lack of recovery of infectious MV (Niewiesk
et al., 1997). Our results confirm and extend these find-
ings, suggesting that CD46 expression is not sufficient in
vivo to render rodents susceptible to MV infection, al-
though explanted cell cultures could grow virus.
A recent report indicated that CD46 influences the in
vivo susceptibility of neurons of transgenic mice, and it
was concluded that CD46 should be absolutely essential
to confer susceptibility to infection and disease of the
CNS of mice (Rall et al., 1997). Thus Rall et al., (1997)
found MV antigen in transgenic mouse brains, while no
staining for MV antigen was found in brains of nontrans-
genic mice infected at any age. This notion was not
confirmed in the present study, where MV transcripts and
antigen appeared in the brain of both transgenic and
nontransgenic mice. The discrepancy between our find-
ings in adult mice and those of Rall et al., (1997) in
neonates and adults may be related to the different
TABLE 2
Measles Virus Infection Experiments in CD46-Transgenic and Non-Transgenic Mice
Experiment Viral challengea
Experimental
period (days)
Miceb
MV
isolation
MV antigen
detectionc
Sero-
conversiondn CD46-Tg/non-Tg PBMC Tissue
1 Halle´ 9 2 CD46-Tg ND 2 2 2
5 3 106 PFU i.p. 2 non-Tg ND 2 2 2
2 Halle´ 21 4 CD46-Tg -coculte ND ND 2
5 3 106PFU i.p. 1 non-Tg -coculte ND ND 2
3 Ma93F 10 6 CD46-Tg ND 2 ND 2
2 3 106PFU i.p. 3 non-Tg ND 2 ND 2
4 Halle´ 140 16 CD46-Tg -lungf ND ND 2
4 3 106PFU i.n.
2 3 107PFU i.p.
5 Yagamata 28 12 CD46-Tg 2g ND 1h 2
5 3 103 PFU i.c. 13 non-Tg 2g ND ND 2
6 Edmonston 28 12 CD46-Tg 2g ND ND 2
5 3 105 PFU i.c. 13 non-Tg 2g ND 1h 2
Note. Data on virus isolation, antigen detection, and seroconversion; 1, positive result; 2, negative result; ND, not determined.
a The Halle´ and Edmonston vaccine-related strains, the Ma93F wild-type isolate, and the Yagamata SSPE strain were used. In Experiments 1–4,
the mice received intraperitoneal (i.p.) and/or intranasal (i.n.) viral challenge material purified from culture supernatants. The mice in Experiments 6
and 7 were inoculated intracerebrally (i.c.) with suspended Yagamata-infected Vero cells or purified Edmonston virus.
b Number (n) of CD46 transgenic (CD46-Tg) and nontransgenic (non-Tg) mice.
c Peripheral blood mononuclear cells (PBMC) were tested for intracellular MV antigen by indirect immunofluorescence test (IF) on microscope
slides and for cell surface antigen by cytofluorometry. PBMC were tested on Days 3, 6, and 9 postinoculation in Experiment 1 and on each day from
Day 3 to 10 postinoculation in Experiment 3. Cryo sections of lung, thymus, and spleen tissue were examined for viral antigen by IF on Days 6 and
9 postinoculation.
d Examination for MV antibodies in serum samples, taken the first day and at the end of the experimental period, was done by virus neutralization test.
e PBMC harvested from two mice at each time point was tested on Days 3, 6, 9, 11, 15, and 18 postinoculation for infectious MV by cocultivation
with Vero cells.
f Lung tissue from two mice harvested on Day 5 postinoculation was tested for infectious MV in Vero cell cultures.
g Brain tissue harvested from individual mice on Days 7 and 14 was tested for infectious MV in Vero cell cultures.
h In cryo sections of brain tissue harvested on Day 14 MV antigen was detected in hippocampus.
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mouse lines investigated. In the present studies, intra-
cerebral inoculation of either the Edmonston (vaccine) or
the Yamagata (SSPE) strains induced MV RNA tran-
scripts during the first 4 weeks postinoculation in the
same areas in the transgenic and nontransgenic mice,
including the frontal cortex, hippocampus, and cerebel-
lum. The cerebellum seemed to permit a more restrictive
viral multiplication compared to the other brain struc-
tures examined. Determinants for the restricted viral mul-
tiplication in cerebellum might include susceptibility of
the specific cell types to infection or physical restrictions
to virus spread in rodents. A similar distribution of viral
antigen has been observed in mice after intracerebral
inoculation of the closely related canine distemper virus
(CDV) (Bernard et al., 1993), while in dogs, a natural CDV
host, the virus infection induces a panecephalitis with
cerebellar sites consistently involved (Summers and Ap-
pel, 1994). Interestingly, in cases of SSPE in humans the
TABLE 3
Detection of Measles Virus F Transcripts in CD46 Transgenic and Nontransgenic Mice after Intraperitoneal and Intranasal Viral Exposure
Experiment Viral challenge
Days
postinoculation
Mice a Tissue
n CD46-Tg/non-Tg Lung Spleen Kidney Intestine
3 Ma93F 4 2 CD46-Tg 1/2 2/2 2/2 2/1
1 non-Tg 2 2 2 2
7 1 CD46-Tg 2 2 2 2
1 non-Tg 2 2 2 2
10 2 CD46-Tg 2/2 2/2 2/2 2/2
1 non-Tg 2 2 2 2
4 Halle´ 2 2 CD46-Tg 1/2 2/2 1w/2 1w/1w
5 2 CD46-Tg 1w/2 2/2 2/2 2/1w
7 2 CD46-Tg 1/2 2/2 2/2 2/2
14 2 CD46-Tg 2/2 2/2 2/2 2/2
21 2 CD46-Tg 2/2 2/2 2/2 2/2
Control b — 2 CD46-Tg 2/2 2/2 2/2 2/2
Note. Data on RNA extractions examined for F transcripts by RT–PCR and Southern blot; 1, positive; 1w, weak positive; 2, negative.
a Number (n) of CD46 transgenic (CD46-Tg) and nontransgenic (non-Tg) mice.
b Two transgenic noninoculated mice served as negative controls.
TABLE 4
Detection of Measles Virus F Transcripts in CD46 Transgenic and Nontransgenic Mice after Intracerebral Viral Exposure
Mice group Viral challenge Mice (n) a Brain tissue b
Days postinoculation
4 7 14 21 28
CD46-Tg c YAG d 2 frontal cortex 1 2 1 11 1
hippocampus 11 11 1 11 11
cerebellum 1 2 2 1 2
EDM e 2 frontal cortex 11 11 11 11 11
hippocampus 11 11 11 11 11
cerebellum 11 11 2 1 2
non-Tg c YAG 2 frontal cortex 1 11 1 1 11
hippocampus 11 11 11 11 11
cerebellum 1 11 1 1 2
EDM 2 frontal cortex 11 11 2 2 1
hippocampus 11 11 1 1 1
cerebellum 11 11 2 2 1
Note. Data on RNA extraction of brain tissue specimens examined for F transcripts by RT–PCR and Southern blot; 11, positive in both mice tested;
1, positive in one of the two mice tested; 2, negative in both mice tested.
a Number (n) of mice.
b Brain tissue of four mice (two transgenic and two nontransgenic mice) Day 14 post mock-inoculation served as negative controls.
c Tg, transgenic.
d Yagamata SSPE strain (see Table 2, Experiment 6).
e Edmonston vaccine strain (see Table 2, Experiment 7).
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MV infection has also been described to involve the
cerebellum (Allen et al., 1996; Baczko et al., 1993).
Our results of intracerebral viral challenge clearly indi-
cate that factors other than CD46 govern the uptake of MV
in cells of neural tissue of mice. Based on the described
inhibitory effect on virus-cell fusion induced by the sub-
stance P, this neuropeptide receptor has been proposed to
play a role in MV entry (Schroeder, 1986; Harrowe et al.,
1990, 1992). It is of interest to further pursue the possibility
of neuroreceptors being alternative receptors for uptake,
replication, and spread of MV in tissues of the central
nervous system in rodents and man.
The results presented here support the idea that effi-
cient MV replicative cycles characteristic of fully permis-
sive host cells require other factors in addition to CD46,
that are lacking in nonsusceptible tissues of transgenic
mice.
There are several possible explanations for the re-
stricted MV replication in transgenic mouse cells that
express CD46 such as the lack of coreceptor factors
and/or additional factors required for later stages in viral
replication. Only recently has evidence for another un-
identified receptor for MV on marmoset B cells appeared
(Hsu et al., 1998).
From studies on CD46 transgenic murine macro-
phages, a block of MV replication between virus tran-
scription and protein synthesis has previously been re-
ported (Horvat et al., 1996).
Our studies on transgenic murine lung and kidney cell
cultures did not reveal a total block of MV replication;
however, replication with release of infectious extracel-
lular virus was highly inefficient compared to that of
primate cell cultures.
The creation of a suitable small animal model for MV
infection by use of transgene technology awaits further
insights into the crucial factors necessary for MV repli-
cation in vivo and in vitro.
MATERIALS AND METHODS
CD46-transgenic mice
Transgenic mice were generated by microinjection of
an 80-kb human CD46 genomic construct into fertilized
Black6/SJL mouse oocytes. Thirteen founder mice were
obtained, and seven were bred for analysis of G1 off-
spring. Mice from all seven lines expressed the full-
length 3.2-kb human CD46 message in various tissues at
levels comparable to that seen in human tissues (data
not shown). Nontransgenic mouse RNA did not hybridize
to the human CD46 probe. RT–PCR analysis of RNA from
transgenic mouse tissues (liver, heart, kidney, and
spleen) to identify expression of various CD46 isoforms
(Johnstone et al., 1993) demonstrated the same pattern
as that seen in corresponding human tissues (data not
shown). Nontransgenic BALB/c and F1 generation of
Black6/SJL were purchased from IFFA-CREDO, France.
A colony of mice based on the offspring of the original
Black6/SJL (H-2b) transgenic mouse line 29–3 (which
carries 1 copy of the CD46 transgene) and the F1, F5, and
F6 generations of crossings with BALB/c (H-2d) were
used in infection studies with MV. The mice were
screened for the expression of the transgene on periph-
eral blood mononuclear cells (PBMC) by flow cytometric
analysis as described below, and the transgene was
found to be expressed in all cells of the B and T subset.
CD46 was detected in lung and thymus of transgenic
mice by immunofluorescence, while CD46-negative lit-
termates were used as controls. CD46 transcripts were
detected in various organs including lung, thymus, kid-
ney, liver, intestine, and brain by RT–PCR on total RNA
extractions and subsequent hybridization of Southern
blots as described below.
Preliminary results suggested that CD46 is functional
in the transgenic mice as assessed by the ability to
protect white blood cells from complement-mediated cy-
totoxicity (data not shown).
MV inoculations in vivo. Inoculation in mice (4–12
weeks old) was performed intranasally (40 ml, 4 3 106
plaque-forming units (PFU)) after ether anesthesia, intra-
peritoneally in a 200 ml volume (2 3 106 to 2 3 107 PFU
or 106 infected cells) or by the intracerebral route with a
20- to 30-ml volume (5 3 103 PFU and 5 3 106 PFU).
Uninoculated mice, sham-infected mice inoculated
with uninfected cell suspensions or MEM alone served
as controls. The inoculated mice were checked for clin-
ical symptoms daily.
Virus and cells
Monolayer cell cultures were established from lung
and kidney tissue of CD46-transgenic and nontransgenic
mice (Black6/SJL) essentially as described previously
(Blixenkrone-Møller et al., 1992).
FIG. 5. Southern blot hybridization. A fragment (452 bp) of the fusion
protein gene of MV was amplified by RT-PCR on polyadenylated RNA
extracted from mouse brain tissue (see text). The PCR products were
electrophoresed, transferred to nylon membranes, and probed with a
32P-labeled internal 30 mers oligonucleotide probe (see text). Transgenic
mice (1) and nontransgenic mice (2), controls (c). Lane 1, Day 14 after
Yamagata inoculation; lane 2, Day 14 after Edmonston inoculation; lanes 3
and 4, Days 7 and 28, respectively, after Edmonston inoculation; lane 5,
negative control (rat glioma cell line, C6); lanes 6 and 7, positive PCR
controls, (MV-infected Vero cells, Halle´ and Yamagata, respectively).
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Vero cells, HeLa cells, and the established murine
lung and kidney cultures were grown in DMEM supple-
mented with 10 mM HEPES, 2 mM L-glutamine, fetal calf
serum (2–20%), and antibiotics.
Experiments were carried out with the following MV
strains/isolates propagated in Vero cells: (i) Edmon-
ston vaccine (Rouvax) strain originally obtained from
Institut Me´rieux; (ii) Halle´, a vaccine-like strain (Horta-
Barbosa et al., 1971); (iii) Y15 a wild-type isolate
adapted to Vero cells (Giraudon et al., 1988); (iv)
MA93F, a recent Spanish wild-type isolate (Rima et al.,
1995) adapted to Vero cells; and (v) Yamagata, an
SSPE strain (Homma et al., 1982). Except for the latter,
virus was purified from cell culture supernatants by
ultracentrifugation (90 min at 110,000 g) in a 30–50%
(w/v) discontinuous sucrose gradient; the virus band in
the interphase was collected and pelleted by centrif-
ugation in PBS containing 1 mM-EDTA. The pellet was
resuspended in PBS and stored at 280°C.
Virus isolation from PBMC and from fresh post-mortem
tissue was as previously described (Blixenkrone-Møller
et al., 1992). Briefly, subconfluent Vero cell cultures were
overlaid with 105–106 PBMC with a ratio of PBMC to Vero
cells from 1:1 to 1:10. Homogenized lung and brain tissue
10% w/v serially diluted were inoculated on subconfluent
Vero cells. On Day 4–5 post-cocultivation the Vero cells
were trypsinized and passaged. The cultures were mon-
itored for viral antigen by immunofluorescence (IF) after
a further 10–12 days.
Stocks of the vaccinia recombinant virus encoding the
MV H and F proteins (VVR’H1F) (Drillien et al., 1988; Wild
et al., 1992) were propagated as reported previously
(Wild et al., 1992).
Murine specimens from in vivo experiments
Blood was collected from the tails of the mice. PBMC
were isolated from EDTA-stabilized samples by centrifu-
gation (500 g, 20 min) on a Ficoll density gradient (Dia-
trizoate–Ficoll, 1.077 g/ml, Eurobio, France) and washed
twice in RPMI. For intracellular IF, approximately 50,000
cells were air-dried on microscope slides prior to fixation
in acetone at 220°C for 5 min.
Mouse tissue specimens from lung, thymus, liver,
spleen, small intestine, and kidney were collected, snap-
frozen in liquid nitrogen, and stored at 280°C. For IF
cryostat sections were mounted on glass slides and
fixed in acetone. Brain specimens were collected from
mice, which had been perfused under deep anesthesia
with cold 0.1 M phosphate-buffered saline (PBS), pH 7.4,
to remove blood components. Specimens for RT–PCR
from the frontal cortex, hippocampus, and cerebellum
were microdissected from the mouse brains prior to
storage at 280°C.
RNA extractions, RT–PCR, and Southern blotting
Total RNAs were extracted from 10 to 100 mg of tissue
or 5–10 3 106 cultured cells according to the methods of
Chomzynski and Sacchi (1987). First-strand cDNAs were
synthesized from 3 mg of total RNA using reverse tran-
scriptase (Promega, Madison, WI) under conditions de-
scribed previously (Bencsik et al., 1996). For MV F am-
plifications, oligo(dT)-primed cDNAs were used, while
CD46 amplifications were primed with the CD46-specific
antisense primer (see below) using AmpliTaq DNA poly-
merase (Perkin-Elmer, Cetus, France) (Bencsik et al.,
1996). Primers with expected amplicons of 451 and 381
bp for MV F and CD46, respectively, were purchased
from Genosys (Cambridge, UK). For amplification of MV-
specific gene sequences, a primer pair (59GGCAATT-
GAGGCAATCAGACA39 and 59CTTGAGAGCCTATGTTGT-
ACG39) corresponding to mRNA sense and antisense of
the MV F gene sequence was used. The DNA was
PCR-amplified 1 min at 95°C, 1 min at 55°C, 1.5 min at
72°C during 40 cycles, followed by 15 min at 72°C.
The selected CD46 primers [59-ATGGCTACCTGTCTC-
AGATGACGC-39, which corresponds to mRNA sense nu-
cleotide (nt) 298–321 and 59-GTCACCACAATAAATCG-
TGC-39 antisense nt 679–660, EMBL/GenBank data-
base Accession No. Y00561 (Lublin et al., 1988)] were
run in PCR under the same conditions as given above.
The quality and quantity of the RNA and the cDNA
were monitored by PCR-amplification of the mouse
glyceraldehyde phosphate dehydrogenase gene as
detailed previously (Bencsik et al., 1996). The PCR
products were analyzed by electrophoresis on a 1%
agarose gel, and amplicons of expected sizes (452 bp
for MV-F and 381 bp for CD46) were visualized by
ethidium bromide staining.
The PCR products of the MV F gene and CD46 protein
gene were further analyzed by transfer to a positively
charged nylon membrane (Hybond N1, Amersham, UK)
and probed with 59-end labeled [g-32P]ATP internal oli-
gonucleotides, 59-CCCGGATAACTCACGTCGACACAGA-
GTCCT-33 (Esolen et al., 1993) and 59-AAATGGCCAAG-
CAGTCCCTGC-39, respectively.
All preparations from uninoculated or sham-inocu-
lated mice and total RNA of the established murine
lung cell cultures and of a rat glioma cell line (C6)
were examined by RT and PCR with the MV F primer
pairs as negative controls. Similarly, first-strand prod-
ucts of nontransgenic mice were run with the CD46
primer pair as negative controls. Preparations from
HeLa cells and from Vero cells infected with the vari-
ous MV strains, and isolates were used in RT–PCR as
positive controls for CD46 and MV F, respectively.
‘‘Negative’’ control samples lacking cDNAs did not
produce any amplification bands.
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Antibodies, immunofluorescence, flow cytometry, and
serology
Mouse monoclonal antibodies (MAbs) against the MV
structural proteins, anti-nucleoprotein (N) protein MAbs
(125, 25), anti-matrix protein (M) MAbs (A2123, B117, gift
of V. ter Meulen), anti-F MAb (F3) (de Vries et al., 1988),
anti-H 55 (Giraudon et al., 1988), and the following anti-
CD46 MAbs: 29, E8/5, E12/4 (E. Malvoisin and J. Fayolle,
unpublished results), MC120.6 (Naniche et al., 1993), and
13/42, 10/88 (gift of J. Schneider-Schaulies, Wu¨rzburg,
Germany) (Schneider-Schaulies et al., 1995) were em-
ployed.
Tissue sections and PBMC preparations on micro-
scope slides were examined for intracellular MV antigen
in an indirect IF test employing a human hyperimmune
serum as primary antibody (dilution 1/500) and a 1/40
dilution of rabbit anti-human IgG F (ab9)2 fragments con-
jugated to fluorescein isothiocyanate (FITC) (Dako,
Glostrup, Denmark). Tissue sections were blocked with
5% normal rabbit serum in PBS before incubation with
specific antibodies diluted in PBS containing 2% normal
rabbit serum.
The cultured cell preparations and tissue sections
from brain were reacted with anti-MV MAbs in an indirect
IF technique essentially as previously described (Blixen-
krone-Møller et al., 1992). Specific MAb ascites fluids
diluted 1/200 or 1/500 served as the primary antibody,
FITC-conjugated rabbit anti-mouse IgG F(ab9)2 fragments
diluted 1/100 (Dako) or 1/200 (Boehringer) were used as
second layer. Cell preparations from infected and unin-
fected Vero cells served as controls in all IF testings.
Flow cytometric analyses. For detection of cell mem-
brane-associated CD46, the MAbs E8/5, MCI20.6, or an
unrelated mouse MAb diluted 1/500 in FACS buffer (PBS
containing 4% fetal calf serum, 30 mM HEPES, and 0.1%
NaN3), were incubated with cells (5 3 10
5) on ice for 30
min in a 50 ml volume. After two washes, cells were
incubated on ice for a further 30 min with secondary
antibody at a 1/100 dilution in FACS buffer. FITC-labeled
rat anti-mouse IgG1, heavy-chain specific (Serotec, clone
LO-MG1–2, Oxford, U.K.) were used for PBMC, while
cultured cells were incubated with FITC-labeled rabbit
anti-mouse IgG F(ab9)2 fragments (Dako). The washed
(twice in FACS buffer) cells were analyzed on a FACScan
analyzer (Becton Dickinson, San Jose, CA).
To screen mice for the expression of the CD46 trans-
gene, PBMC were incubated for 30 min on ice with a
1/100 dilution of FITC-labeled MAb E8/5, designated FI-
CD46, or an unrelated FITC-labeled mouse antibody in
50 ml FACS buffer. For identification of the T and B cell
populations, FITC-conjugated MAb anti-mouse Thy 1,2
(Becton Dickinson), biotinylated MAb anti-mouse CD311
(originally obtained from A. Glasebrook, Lilly Research
Laboratories, Indianapolis, IN), and avidin-phycoerythrin
(Sigma, St. Louis, MO) were used, and for investigation of
their association with CD46, double staining with FI-
CD46 and biotinylated MAb anti-Thy 1,2 or anti-CD311
and avidin-phycoerythrin were employed.
Serology. Virus neutralization tests in Vero cells were
performed according to the method described previously
(Blixenkrone-Møller et al., 1991). Serial twofold dilutions
of sera starting at 1/20 were incubated with 25 PFU of
MV All samples were tested in duplicate. The highest
dilution of the serum sample neutralizing MV was given
as the titer.
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